GHK — glycyl-L-histidyl-L-lysine — is a three-amino-acid peptide with an outsized reputation and an unusually well-documented origin. Strip away the "anti-aging" marketing and what remains is a copper-binding tripeptide with a real body of research in collagen, skin, and wound-healing models. This is an educational research overview, discussed strictly in a research-use-only context. Nothing here is medical, cosmetic, dosing, or usage guidance.
The origin: young plasma, aged tissue
In 1973, biochemist Loren Pickart was studying why liver tissue from older donors behaved differently from younger tissue. He noticed something odd: adding plasma from young (20-something) donors made aged liver tissue start synthesizing protein the way young tissue does. It took years of work to isolate the responsible factor — and it turned out to be a tiny peptide of just three amino acids, glycine, histidine, and lysine, that carries a copper ion. Human plasma carries roughly 200 µg/L of GHK at age 20, dropping to around 80 µg/L by age 60 — a decline that framed much of the early research interest.
Why the copper matters
GHK has a high, specific affinity for copper(II), forming the complex written GHK-Cu. In research models the peptide is studied largely as a copper-delivery and copper-modulating molecule: copper is a cofactor for enzymes involved in connective-tissue crosslinking, and much of the mechanistic literature centers on how the GHK-Cu complex participates in those pathways rather than on the bare peptide alone. It is one reason "GHK" and "GHK-Cu" are not quite interchangeable terms in the literature.
What the research literature actually studies
The published research clusters around a few themes, almost all preclinical (cell and animal models):
- Collagen and extracellular matrix — models of collagen and glycosaminoglycan synthesis and connective-tissue remodeling.
- Wound and tissue repair — skin and dermal-repair models, where the copper-cofactor angle overlaps with matrix work.
- Gene-expression signatures — broader transcriptomic studies asking which pathways the peptide shifts, which is where a lot of the modern interest sits.
As with most research peptides, the honest read is that the model data are genuinely interesting and the human clinical picture is far thinner than the online summaries imply. "Studied in models" is the accurate phrase.
The documentation point
Because GHK-Cu is a copper complex, identity and purity questions matter more than for a bare peptide, not less: the copper stoichiometry and the peptide purity are separate facts, and both belong on a certificate of analysis. A tube labeled "GHK-Cu" tells you almost nothing on its own. Identity confirmed by mass spectrometry and purity measured by HPLC — per lot — are what turn a label into characterized research material.
The bottom line: the "Pretty Boy Peptide" nickname is fifty years newer than the molecule, and the real story is a copper-binding tripeptide that fell out of a question about why old tissue and young tissue behave differently. The research is real, mostly preclinical, and worth reading honestly rather than through a marketing lens.